Establishing the degree of control in patients with atopic dermatitis with the atopic dermatitis control tool (ADCT)
Main Article Content
Keywords
atopic, dermatitis, degree, disease, control
Abstract
Background: Atopic dermatitis (AD) is a disease of multifactorial etiology that affects the quality of life of those afflicted.
Objective: The degree of control of patients with AD over 12 years of age was determined with the Atopic Dermatitis Control Instrument (ADCT).
Material and Methods: This observational, cross-sectional, descriptive study included patients with AD who were evaluated with a self-administered instrument, the ADCT. Pearson’s Chi square and Student’s t-tests were used for categorical variables. The association between continuous variables was analyzed with the Pearson and Spearman correlations.
Results: A total of 55 patients with AD were included—42 women (76.4%) and 13 men (23.6%). The median age was 24 years (12–63). Regarding the degree of disease control, it was adequate in 23 (41.8%) patients and inadequate in 32 (58.2%). The patient’s sex, age, work activity, residence, and level of education were not statistically significant factors for the degree of control. The most prevalent comorbidity was allergic rhinitis with a higher percentage in those with adequate control (p = 0.049). Treatment with corticosteroids was associated with good disease control (p <0.001). A high positive correlation (r = 0.770, p < 0.001) was found between the SCORAD score and the ADCT score for symptom control. SCORAD and POEM scores showed a direct proportional relationship (r = 0.791; p < 0.001)
Conclusions: The ADCT allowed us to determine the degree of control of atopic dermatitis and develop treatment strategies.
References
2 Paras V, Silverberg J. Adult-onset atopic dermatitis: Characteristics and management. Am J Clin Dermatol. 2019;20(6):771–79. 10.1007/s40257-019-00453-7
3 Pariser D, Simpson E, Gadkari A, Bieber T, Margolis D, Brown M, et al. Evaluating patient-perceived control of atopic dermatitis: Design, validation, and scoring of the atopic dermatitis control tool (ADCT). Curr Med Res Opin. 2020;36(3):367–76. 10.1080/03007995.2019.1699516
4 Guevara Sanginés E, Pérez Rojas D, Nevárez Sida A, Aceves M, Barrón Tapia M, Abaroa Cantú F, et al. Costo anual de la atención médica de pacientes con dermatitis atópica moderada a grave en México. Estudio multicéntrico. Rev Alerg Mex. 2020;67(1):9–18. 10.29262/ram.v67i1.700
5 Sandoval Ramírez E, del Rio B, del Río Chivardí J, Pietropaolo Cienfuegos D, Rosas Vargas M, Avila L, et al. Prevalence and associated risk factors for atopic dermatitis symptoms in Mexican children. World Allergy Organ J. 2012;5:S15–S16.10.1097/01.WOX.0000411791.20709.40
6 Herrera Sánchez D, Segura Méndez N, Hernández Ojeda M, Vivas Rosales I. Estudio epidemiológico sobre dermatitis atópica en México. Rev Alerg Mex. 2019;66(2):192–4. 10.29262/ram.v66i2.591
7 Solé D, Mallol J, Wandalsen GF, Aguirre V; Latin American ISAAC Phase 3 Study Group. Prevalence of symptoms of eczema in Latin America: Results of the international study of asthma and allergies in childhood (ISAAC) Phase 3. J Investig Allergol Clin Immunol. 2010;20(4):311–23.
8 Simpson E, Eckert L, Gadkari A, Mallya U, Yang M, Nelson L, et al. Validation of the atopic dermatitis control tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis. BMC Dermatol. 2019;6;19:1510.1186/s12895-019-0095-3
9 Staumont-Sallé D, Taieb C, Merhand S, Shourick J. The atopic dermatitis control tool: A high-performance tool for optimal support. Acta Derm Venereol. 2019;101(12):adv00618. 10.2340/actadv.v101.750
10 A healthy lifestyle-WHO recommendations. 6 May 2010. Available at: https://www.who.int/europe/news-room/fact-sheets/item/a-healthy-lifestyle---who-recommendations [consulted on August 13, 2023]
11 Charman C, Venn A, Ravenscroft J, Williams H. Translating patient-oriented eczema measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods. Br J Dermatol. 2013;169(6):1326–32. 10.1111/bjd.12590
12 Wollenberg A, Christen Zäch S, Taieb A, Paul C, Thyssen J, Bruin Weller M, et al. ETFAD/EADV eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020;34(12):2717–44. 10.1111/jdv.16892
13 Rincón Pérez C, Larenas Linnemann D, Figueroa Morales MA, Luna Pech J, García Hidalgo L, Macías Weinmann A, et al. Consenso mexicano para el diagnóstico y tratamiento de la dermatitis atópica en adolescentes y adultos. Rev Alerg Mex. 2018;65:S8–S88. 10.29262/ram.v65i6.526
14 Leshem Y, Chalmers J, Apfelbacher C, Katoh N, Gerbens L, Schmitt J, et al. Outcome measures for eczema (HOME) initiative. Measuring atopic eczema control and itch intensity in clinical practice: A consensus statement from the harmonising outcome measures for eczema in clinical practice (HOME-CP) Initiative. JAMA Dermatol. 2022;158(12):1429–35. 10.1001/jamadermatol.2022.4211
15 Stuart L, Howells L, Pattinson R, Chalmers J, Grindlay D, Rogers N, et al. Measurement properties of patient-reported outcome measures for eczema control: A systematic review. J Eur Acad Dermatol Venereol. 2021;35(10):1987–93. 10.1111/jdv.17335
16 Li A, Zhang M, Yang Y, Zhang J, Xie X, Li X, et al. Patient-reported outcome (PRO) instruments for disease severity and quality of life in patients with atopic dermatitis: A systematic review of English and Chinese literature. Ann Transl Med. 2022;10(16):906. 10.21037/atm-22-3164
17 Oosterhaven J, Spekhorst L, Zhang J, Voorberg A, Romeijn G, Boesjes C, et al. Eczema control and treatment satisfaction in atopic dermatitis patients treated with dupilumab–a cross-sectional study from the BioDay registry. J Dermatolog Treat. 2022;33(4):1986–89 10.1080/09546634.2021.1937485
18 Parra Jaramillo L, Ramírez Rico A, Morales Sánchez M. Dermatitis atópica en adultos durante la pandemia por COVID-19. Rev Alerg Mex. 2022;69(2):72–7. 10.29262/ram.v69i2.1067
19 Kimball A, Delevry D, Yang M, Chuang C, Wang Z, Bégo-Le-Bagousse G, et al. Long-term effectiveness of dupilumab in patients with atopic dermatitis: Results up to 3 years from the RELIEVE-AD Study. Dermatol Ther. 2023;13(9):2107–20. 10.1007/s13555-023-00965-5
20 Staumont-Sallé D, Taieb C, Merhand S, Shourick J. The atopic dermatitis control tool: A high-performance tool for optimal support. Acta Derm Venereol. 2021;101(12). 10.2340/actadv.v101.750
21 Simpson E, Eckert L, Gadkari A, Mallya U, Yang M, Nelson L, et al. Validation of the atopic dermatitis control tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis. BMC Dermatol. 2019;19(1):15. 10.1186/s12895-019-0095-3
22 Mandelin J, Ekman A, Ruohonen S, Korhonen L. Atopic dermatitis patients’ preference on patient self-administered tools used in clinical practice. Acta Derm Venereol. 2023;103:adv5261. 10.2340/actadv.v103.5261
23 Coutanceau C, Stalder J. Analysis of correlations between patient-oriented SCORAD (PO-SCORAD) and other assessment scores of atopic dermatitis severity and quality of life. Dermatology. 2023;229(3):248–55. 10.1159/000365075
24 Silverberg J, Lei D, Yousaf M, Janmohamed S, Vakharia P, Chopra R, et al. Comparison of patient-oriented eczema measure and patient-oriented scoring atopic dermatitis vs eczema area and severity index and other measures of atopic dermatitis: A validation study. Ann Allergy Asthma Immunol. 2023;125(1):78–3. 10.1016/j.anai.2020.03.006
